Related Experiment Video
Updated: May 10, 2026
06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone
Xiuqin Zhang1, Rongli Zhang, Susanne Raab
1Institute of Molecular Medicine, Peking University, No.5 Yiheyuan Rd, Haidian District, Beijing 100871, China.
Circulation
|June 22, 2011
Summary
Metabolic syndrome (MetS) components track together, linking metabolic and cardiovascular issues. Pioglitazone treatment reversed vascular dysfunction, supporting shared mechanisms and early intervention for MetS.
Area of Science:
- Metabolic and cardiovascular research
- Primate models of human disease
- Pharmacological interventions
Background:
- Metabolic syndrome (MetS) is a cluster of conditions including obesity, hypertension, dyslipidemia, and insulin resistance.
- The underlying pathophysiology of MetS, whether shared mechanisms or coincidental risk factors, remains debated.
Purpose of the Study:
- To investigate the coemergence of metabolic and cardiovascular components during MetS development.
- To explore the mechanistic link between MetS and vascular dysfunction.
- To evaluate the therapeutic potential of pioglitazone in MetS.
Main Methods:
- Identification and monitoring of MetS-predisposed rhesus macaques over 18 months.
- Assessment of metabolic and cardiovascular parameters, including flow-mediated dilation.
- Treatment of MetS animals with pioglitazone, a PPARγ agonist.
Main Results:
- MetS components tracked together during disease progression in rhesus macaques.
- MetS was associated with significant impairment of flow-mediated dilation, indicating vascular dysfunction.
- Pioglitazone treatment improved dyslipidemia and insulin resistance, fully restoring vascular function.
Conclusions:
- Shared pathophysiological mechanisms underlie MetS development and cardiovascular complications.
- Early intervention targeting MetS components is beneficial.
- Nonhuman primate models are valuable for MetS research and translational studies.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.